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Aims Frailty, characterized by loss of homeostatic reserves and increased vulnerability to physiological decompensation,
results from an aggregation of insults across multiple organ systems. Frailty can be quantified by counting the number
of ‘health deficits’ across a range of domains. We assessed the frequency of, and outcomes related to, frailty in patients
with heart failure and reduced ejection fraction (HFrEF).
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Methods
and results
Using a cumulative deficits approach, we constructed a 42-item frailty index (FI) and applied it to identify frail
patients enrolled in two HFrEF trials (PARADIGM-HF and ATMOSPHERE). In keeping with previous studies, patients
with FI ≤0.210 were classified as non-frail and those with higher scores were divided into two categories using
score increments of 0.100. Clinical outcomes were examined, adjusting for prognostic variables. Among 13 625
participants, mean (± standard deviation) FI was 0.250 (0.10) and 8383 patients (63%) were frail (FI >0.210). The
frailest patients were older and had more symptoms and signs of heart failure. Women were frailer than men. All
outcomes were worse in the frailest, with high rates of all-cause death or all-cause hospitalization: 40.7 (39.1–42.4)
vs. 22.1 (21.2–23.0) per 100 person-years in the non-frail; adjusted hazard ratio 1.63 (1.53–1.75) (P< 0.001). The
rate of all-cause hospitalizations, taking account of recurrences, was 61.5 (59.8–63.1) vs. 31.2 (30.3–32.2) per 100
person-years (incidence rate ratio 1.76; 1.62–1.90; P< 0.001).
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Conclusion Frailty is highly prevalent in HFrEF and associated with greater deterioration in quality of life and higher risk of
hospitalization and death. Strategies to prevent and treat frailty are needed in HFrEF.
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Introduction
Frailty is defined as a multisystem disorder characterized by loss
of homeostatic reserves, rendering affected individuals vulnerable
to physiological decompensation and placing them at increased
risk of adverse outcomes when exposed to a stressor.1 Frailty
is thought to result from an aggregation of insults across multi-
ple organ systems.2 Importantly, frailty is related to, but distinct
from, both aging and comorbidity.1,3 Younger individuals may be
frail and frailty is often associated with problems not specific to
a particular disease such as fatigue, poor appetite and reduced
mobility.1–4 There is particular interest in the relationship between
frailty and cardiovascular disease for a number of reasons.5 First,
cardiovascular disease may accelerate development of frailty and
frailty may worsen outcomes related to cardiovascular disease.6
Both cardiovascular disease and frailty may share common patho-
physiological mechanisms, like inflammation, and have common
consequences, such as exercise intolerance, leading to a vicious
cycle of decline. Moreover, frailty may be an ‘effect modifier’,
adversely affecting the risk–benefit profile of both pharmacolog-
ical and non-pharmacological interventions, for example surgery
and device implantation.7,8
We have studied the prevalence and importance of
frailty in heart failure (HF) with reduced ejection frac-
tion (HFrEF) in the Prospective comparison of ARNI
(Angiotensin Receptor–Neprilysin Inhibitor) with ACEI
(Angiotensin-Converting Enzyme Inhibitor) to Determine
Impact on Global Mortality and morbidity in Heart Failure
trial (PARADIGM-HF, ClinicalTrials.gov NCT01035255) and the
Aliskiren Trial to Minimize OutcomeS in Patients with HEart
failuRE trial (ATMOSPHERE, ClinicalTrials.gov NCT00853658)
using the Rockwood cumulative deficit approach.9–11
Methods
Trials and participants
The inclusion and exclusion criteria of PARADIGM-HF and ATMO-
SPHERE were almost identical. Briefly, patients were eligible at screen-
ing if ≥18 years, New York Heart Association (NYHA) class II–IV,
left ventricular ejection fraction (LVEF)≤ 35% (changed from ≤40%
in PARADIGM-HF by amendment), elevated natriuretic peptide (NP)
level, taking an ACEI or angiotensin receptor blocker, beta-blocker
(unless contraindicated/not tolerated) and mineralocorticoid receptor
antagonist, if indicated.9,10
Exclusion criteria included symptomatic hypotension or systolic
blood pressure <95mmHg (<90mmHg in ATMOSPHERE), estimated
glomerular filtration rate <30mL/min/1.73m2 (<35mL/min/1.73m2 in
ATMOSPHERE) and potassium >5.4mmol/L (>5.2mmol/L in ATMO-
SPHERE). Trials were approved by ethics committees at all participating
centres and all patients provided written informed consent.
After a run-in period, patients were randomly assigned to
double-blind therapy with sacubitril/valsartan or enalapril in 1:1
ratio in PARADIGM-HF, or enalapril, aliskiren or combination in 1:1:1
ratio in ATMOSPHERE.
Median duration of follow-up was 26.6 months in PARADIGM-HF
(1 day to 4.2 years) and 36.7 months (1 day to 6.2 years) in ATMO-
SPHERE. ..
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.. Frailty index
We used the cumulative deficits approach to construct a 42-item frailty
index (FI) in patients in PARADIGM-HF and ATMOSPHERE. The FI was
constructed as described by Rockwood where the index, ideally, should
be made up of at least 30 items; variables included must be associated
with health and not part of normal ageing such as presbyopia (but
deficits should generally increase with age); items in the index should
cover a range of body systems; items used must be applied similarly
throughout the sample.11–13 We used 15 questions (of 23) from the
Kansas City Cardiomyopathy Questionnaire (KCCQ, see below) as
proxy measures of disability (an important constituent of frailty and
distinguishes it from multimorbidity) to form the basis for our index.3
The remaining 27 items were derived from medical history, other
patient characteristics and laboratory results, covering a range of body
systems (online supplementary Table S1). We excluded eight questions
from the KCCQ used to construct the symptom severity, frequency
and burden domains to avoid defining the FI by HF symptoms.14 Binary
variables were scored 0/1 (absent/present); ordinal variables were
scored from 0–1, 1 indicating greatest severity. Continuous variables
were dichotomized and scored as 0/1 (normal/non-normal). Patients
with ≥20% missing variables were excluded from the analysis.15,16 FI
score was calculated using the recommended approach, i.e. sum of the
deficits divided by total number of non-missing deficits assessed. In
this study, patients with FI ≤0.210 were classified as non-frail based on
conventional cutoffs used by most authors; those with higher scores
were further divided into two categories using increments in score of
0.100.11,17
Outcomes
Primary outcome for both trials was the composite of HF hospital-
ization or cardiovascular death. In this study, we analysed the primary
outcome, its components, and cardiovascular, non-cardiovascular and
overall hospitalizations. Recurrent hospitalizations for each of these
causes and reduction in health-related quality of life, as measured by
decrease in KCCQ at 12months, are reported.14
Statistical analysis
Baseline characteristics are reported as means [± standard deviations
(SD)], proportions, or medians (Q1–Q3). Statistical tests employed
were ANOVA, Chi-square test and Kruskal–Wallis test, respectively.
The association between FI and age was compared between men
and women using linear regression. Restricted cubic splines were
employed to assess the relationship between FI and all-cause death,
taking the lowest FI as the reference. Competing risks regression,
using Fine–Gray method, was used to assess outcomes. Primary
outcome and cardiovascular death were analysed accounting for
competing risk of non-cardiovascular death. First HF, cardiovascu-
lar, non-cardiovascular and all-cause hospitalizations were analysed
accounting for competing risk of all-cause death. Non-cardiovascular
deaths were analysed accounting for competing risk of cardiovascular
death. Crude sub-distribution hazard ratios (sHRs) and adjusted sHRs
from models including age, sex, heart rate, N-terminal pro brain natri-
uretic peptide (NT-proBNP), NYHA class, LVEF, duration of HF and
additionally previous hospitalization for HF are reported. For multivari-
able adjustment we chose clinically relevant variables shown in prior
studies to be predictive of death and hospitalization, but which were
not part of the FI (e.g. LVEF, NT-proBNP level). Furthermore, adjusting
for aetiology of HF did not affect results. Cox regression was used to
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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assess risk of the composite outcome of all-cause hospitalization or
all-cause death and all-cause death, with adjustment for variables listed
above. Cox regression analysis was also done for 12 subgroups for
the primary composite outcome and all-cause death. Consistency in
treatment effects across the three classes in PARADIGM-HF was also
assessed using the Cox model.
A decrease in KCCQ clinical summary score (CSS) from baseline
to 12months of ≥5 points was analysed using logistic regression and
is reported as odds ratio adjusted for two models – model 1 for
KCCQ-CSS at baseline and model 2 additionally adjusted for variables
listed above.
Recurrent hospitalizations (HF, cardiovascular, non-cardiovascular
and all-cause) were analysed using negative binomial regression model.
Both crude incidence rate ratio (IRR) and IRR adjusted for the variables
listed above, and previous HF hospitalization, are reported.We also did
a sensitivity analysis for outcomes in patients ≥60 years of age.
All models were adjusted for randomized treatment and region.
All analyses were conducted using Stata version 15 (Stata Corp.,
College Station, TX, USA).
Results
In this HFrEF population, FI was calculable for 13 265 (86.0%)
patients. Mean (± SD) andmedian (interquartile range) FI was 0.250
(0.10) and 0.244 (0.176–0.318), respectively. Range was 0.0–0.686
and 10th and 90th percentiles were 0.126 and 0.382, respectively.
Overall, 4882 patients were in FI class 1 (≤0.210), 4770 in FI
class 2 (0.211–0.310) and 3613 in FI class 3 (>0.311).
Baseline characteristics and medical
history
Age and proportion of women increased with increasing FI
(Table 1). Figure 1 shows density distribution of FI for women com-
pared with men demonstrating a rightward shift in women. Mean
and median FI in men were 0.247 (0.10) and 0.240 (0.173–0.315),
respectively, and 0.261 (0.10) and 0.259 (0.289–0.330), respec-
tively, in women (P< 0.001 for each, men vs. women). FI increased
with age at a similar rate in both sexes (Figure 2).
Heart failure characteristics
The frailest patients had a longer duration of HF and higher rate
of prior HF hospitalization (Table 2). NYHA class distribution was
worst in the frailest: the proportion in NYHA class III/IV in least
frail was 11% compared with 49% in the frailest category.
Congestion was more common in the frailest patients (Table 2).
Fatigue was twice as common in the frailest patients compared to
the non-frail (69% vs. 37%).
The EQ-5D questionnaire was completed by patients enrolled in
PARADIGM-HF (online supplementary Table S2): 81% of non-frail
patients reported no problems in walking, compared to 23% of
the frailest patients; 40% of the frailest patients had problems
with self-care and> 70% reported some problems with performing
day-to-day activities (compared with 3% and 16% of the non-frail,
respectively). Moderate/extreme levels of anxiety/depression were
more common in the frailest patients (53% in frailest compared to
19% in the non-frail). ..
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.. Biomarkers
N-terminal proBNP was notably higher in the frailest patients
(Table 2). Levels of most biomarkers measured (in PARADIGM-HF)
also increased with increasing frailty except for matrix
metalloprotease-9 (online supplementary Table S3).
Baseline treatment
Frailer patients were prescribed more drugs (45% of the frailest
group prescribed >4 drugs compared to 30% in the non-frail)
(Table 2) and higher rates of implantation of a pacemaker,
cardioverter-defibrillator and cardiac resynchronization therapy.
Vaccination and disease management programme enrolment
(in PARADIGM-HF) increased with increasing frailty (online
supplementary Table S4).
Clinical outcomes
Heart failure specific outcomes
Risk of the primary composite outcome and its components
was highest in the frailest, with unadjusted sHRs between 1.89
and 2.14 and adjusted sHRs of 1.69 to 1.75 (Table 3 and
Figure 3).
All-cause death and all-cause hospitalization
The rates of hospitalization for cardiovascular causes and for
any reason were also significantly higher in the frailest patients,
with sHRs of 1.69 (1.55–1.84, P< 0.001) and 1.60 (1.49–1.71,
P< 0.001), respectively (Table 3). Risk of death from any cause
was approximately twice as high in the frailest patients, compared
to the non-frail, although the proportions of deaths that were
cardiovascular and non-cardiovascular were similar across the FI
categories (Table 3). Similar differences in risk of death and hos-
pitalization were observed when frailty was examined across the
different age groups, whether including the complete spectrum of
age, or focussing only on those aged ≥60 years (online supplemen-
tary Tables S5 and S6).
As shown in online supplementary Figure S1, the association
between FI and mortality was most evident at a FI ≥0.20. Risk of
each outcome also increased with every 0.01 increase in the FI
(online supplementary Table S7).
Recurrent events
All outcomes of interest were more common in the frailest
patients (Table 3 and online supplementary Table S8). The adjusted
IRR for HF hospitalization in the frailest participants was 1.90
(1.64–2.20); 1.76 (1.60–1.95) for cardiovascular hospitalization,
1.75 (1.58–1.94) for non-cardiovascular hospitalization, and 1.76
(1.62–1.90) for all-cause hospitalization.
Subgroup analysis
There were no differences in outcomes (primary composite out-
come and all-cause death) among any of the subgroups analysed
except for race as shown in online supplementary Figure S2.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics
FI class 1 (≤0.210)
(n = 4882)
FI class 2 (0.211–0.310)
(n = 4770)
FI class 3 (≥0.311)
(n = 3613)
P-value for trend
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 61.0±11.7 64.9±10.8 67.1±10.3 <0.001
Female sex, n (%) 893 (18.3) 1059 (22.2) 882 (24.4) <0.001
Region, n (%) 0.853
North America 199 (4.1) 265 (5.6) 295 (8.2)
Latin America 1165 (23.9) 671 (14.1) 265 (7.3)
Western Europe and other 1225 (25.1) 1385 (29.0) 1094 (30.3)
Central Europe 1086 (22.2) 1789 (37.5) 1739 (48.1)
Asia-Pacific 1207 (24.7) 660 (13.8) 220 (6.1)
Race, n (%) <0.001
White 2963 (60.7) 3644 (76.4) 3127 (86.6)
Black 207 (4.2) 168 (3.5) 109 (3.0)
Asian 1176 (24.1) 625 (13.1) 209 (5.8)
Other 535 (11.0) 332 (7.0) 167 (4.6)
Systolic blood pressure (mmHg) 119.0± 14.8 123.5±16.6 127.2±17.9 <0.001
Heart rate (bpm) 71.1±11.7 72.0±12.5 72.6±12.5 <0.001
BMIa (kg/m2) 26.4 (23.7–29.6) 27.7 (24.6–31.3) 29.1 (25.7–33.0) <0.001
Comorbidities, n (%)
Hypertension 2599 (53.2) 3460 (72.5) 3040 (84.1) <0.001
Diabetes 982 (20.1) 1619 (33.9) 1635 (45.3) <0.001
Atrial fibrillation 1242 (25.4) 1811 (38.0) 1910 (52.9) <0.001
Valvular heart disease 202 (4.1) 257 (5.4) 200 (5.5) 0.002
Unstable angina 224 (4.6) 573 (12.0) 754 (20.9) <0.001
Myocardial infarction 1409 (28.9) 2219 (46.5) 2105 (58.3) <0.001
Stroke 183 (3.7) 385 (8.1) 495 (13.7) <0.001
Peripheral arterial disease 86 (1.8) 249 (5.2) 436 (12.1) <0.001
COPD 319 (6.5) 588 (12.3) 801 (22.2) <0.001
Renal disease 351 (7.2) 664 (13.9) 874 (24.2) <0.001
Current smoker 709 (14.5) 660 (13.8) 469 (13.0) 0.246
All values are reported as mean± standard deviation except where indicated.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FI, frailty index.
aMedian (interquartile range).
Effect of treatment
with sacubitril/valsartan according
to frailty index
In PARADIGM-HF only, there was no evidence of an interaction
between treatment and frailty for the four endpoints (online
supplementary Figure S3).
Adverse events
The risk of falls and factures increased as frailty increased, although
the numbers of events were small (online supplementary Table
S9). Study drug discontinuation due to adverse event was more
common in the frailest patients (20% vs. 14% in non-frail) (online
supplementary Table S10).
Discussion
Using an accepted methodology, we found that 63% of individu-
als (69% in patients ≥60 years) in this cohort of HFrEF were frail, .
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.. even though they were relatively young and had been selected
for inclusion in clinical trials.11 Frail patients had worse baseline
health-related quality of life (which was more likely to decline
during follow-up) and were about twice as likely to die during
follow-up. They were also significantly more likely to be hospital-
ized for cardiovascular and other reasons. The association between
frailty and worse clinical outcomes persisted after adjustment for
prognostically important factors and NT-proBNP, the single most
powerful predictor of adverse outcomes in HFrEF.
As frailty is considered to result from an aggregation of insults
across multiple organ systems, one approach to quantify frailty is
counting the number of ‘health deficits’, assessed by symptoms,
signs, diseases and disabilities, as well as laboratory, radiographic
and electrocardiographic abnormalities, across a wide range of
domains.2,11 The more deficits accumulated, the more likely a
patient will be frail. This ‘deficit accumulation’ approach allows
calculation of a FI which has proved to be predictive of mortality,
hospitalization and institutionalization in the general population, as
well as in specific diseases.2 Our FI appeared valid as higher scores
were associated with poorer self-reported and physician-assessed
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Frailty in heart failure with reduced ejection fraction 5
0
1
2
3
4
D
en
si
ty
0 .2 .4 .6
Frailty Index
Men Women
Figure 1 Density distribution of frailty index in men and women.
Figure 2 Frailty index according to age in men and women.
functional status and traditional frailty outcomes such as falls.
Moreover, in our restricted cubic spline analysis, the significant
point of inflection in risk of death related to FI was consistent with
the conventional threshold defining frailty (FI ≥0.210).11
To give some context to our findings, the mean FI in the
general population (UK Biobank, n = 500 336), was 0.129 in those
aged 60–65 and 0.139 in ≥65 years (compared with a mean of
0.250 in our patients, a higher score reflecting greater frailty).18
In 2.69 million American Medicare beneficiaries >65 years without .
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. cancer, FI at age 66 was 0.198 and at age 70 was 0.197.19 In
two hypertension trials, the median FI in patients over 80 years
was 0.17 and 0.18, respectively.20,21 In the Systolic Blood Pressure
Intervention Trial (SPRINT), 27% of patients were classified as
frail. In general population studies, 20–30% of individuals are
identified as frail, rising to 43% at the age of 85 years in a large
Canadian study.22 In our patients with a mean age of 64 years,
63% were frail. These striking differences between patients with
HFrEF and those with hypertension, and the general population,
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Heart failure characteristics, clinical features, investigations and treatment
FI class 1 (≤0.210)
(n = 4882)
FI class 2 (0.211–0.310)
(n = 4770)
FI class 3 (≥0.311)
(n = 3613)
P-value for trend
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HF aetiology <0.001
Ischaemic 2122 (43.5) 2961 (62.1) 2675 (74.0)
Non-ischaemic 2422 (49.6) 1643 (34.4) 857 (23.7)
Other/unknown 338 (6.9) 166 (3.5) 81 (2.2)
HF duration <0.001
<1 year 1856 (38.0) 1336 (28.0) 763 (21.1)
1–5 years 1756 (36.0) 1878 (39.4) 1434 (39.7)
>5 years 1268 (26.0) 1555 (32.6) 1416 (39.2)
Previous HF hospitalization 2835 (58.1) 2994 (62.8) 2412 (66.8) <0.001
NYHA class <0.001
I 302 (6.2) 99 (2.1) 25 (0.7)
II 4021 (82.4) 3323 (69.7) 1808 (50.1)
III 540 (11.1) 1320 (27.7) 1702 (47.2)
IV 16 (0.3) 24 (0.5) 73 (2.0)
KCCQ clinical summary scorea 92.7 (85.4–97.9) 77.1 (65.6–85.9) 55.2 (43.3–67.7) <0.001
KCCQ overall summary scorea 89.6 (82.3–95.1) 73.2 (63.0–82.3) 51.3 (40.6–63.5) <0.001
MAGGIC risk scoreb 19.5± 5.0 21.3± 5.4 23.1± 5.5 <0.001
Clinical features
Dyspnoea on exertion 3901 (80.0) 4203 (88.2) 3383 (93.8) <0.001
Orthopnoea 141 (2.9) 270 (5.7) 409 (11.3) <0.001
PND 85 (1.7) 219 (4.6) 374 (10.4) <0.001
Fatigue 1826 (37.4) 2574 (54.0) 2496 (69.2) <0.001
Peripheral oedema 501 (10.3) 1010 (21.2) 1343 (37.2) <0.001
Third heart sound 369 (7.6) 401 (8.4) 334 (9.3) 0.005
JVD 302 (6.2) 430 (9.0) 516 (14.3) <0.001
Investigations
Ejection fractionb (%) 28.5± 6.1 29.4± 5.9 29.8± 5.8 <0.001
NT-proBNPa (pg/mL) 1230 (713–2353) 1435 (787–2708) 1706 (894–3336) <0.001
Haemoglobinb (g/L) 141.1±14.1 139.1±15.7 136.6±17.6 <0.001
Creatinineb (μmol/L) 90.7± 21.6 96.9± 25.0 103.3± 30.5 <0.001
eGFRb (mL/min/1.73m2) 75.7± 22.5 69.0± 20.9 64.1± 20.5 <0.001
Sodiumb (mmol/L) 140.6± 2.8 140.7± 3.1 141.0± 3.5 <0.001
Potassiumb (mmol/L) 4.5± 0.4 4.5± 0.5 4.5± 0.5 0.063
ECG
LVH 774 (15.9) 791 (16.6) 693 (19.2) <0.001
Atrial fibrillation 861 (17.6) 1220 (25.6) 1218 (33.7) <0.001
LBBB 1042 (21.3) 944 (19.8) 715 (19.8) 0.063
RBBB 325 (6.7) 348 (7.3) 337 (9.3) <0.001
QRS durationb (ms) 118.1± 36.2 117.5± 34.9 118.1± 36.0 0.998
Treatment
Diuretics 3677 (75.3) 3885 (81.4) 3104 (85.9) <0.001
Digoxin 1495 (30.6) 1362 (28.6) 1060 (29.3) 0.149
ACEI 4352 (89.1) 4191 (87.9) 3188 (88.2) 0.154
ARB 551 (11.3) 612 (12.8) 460 (12.7) 0.032
MRA 2522 (51.7) 2288 (48.0) 1669 (46.2) <0.001
CCB 283 (5.8) 472 (9.9) 473 (13.1) <0.001
Statins 2301 (47.1) 2738 (57.4) 2287 (63.3) <0.001
Aspirin 2418 (49.5) 2485 (52.1) 1920 (53.1) 0.001
Anticoagulants 1277 (26.2) 1610 (33.8) 1484 (41.1) <0.001
≥5 drugsc 1468 (30.1) 1826 (38.3) 1606 (44.5) <0.001
PCI 675 (13.8) 675 (13.8) 1064 (29.4) <0.001
CABG 435 (8.9) 818 (17.1) 842 (23.3) <0.001
Pacemaker 473 (9.7) 616 (12.9) 587 (16.2) <0.001
ICD any 656 (13.4) 814 (17.1) 687 (19.0) <0.001
ICD only 460 (9.4) 554 (11.6) 458 (12.7) <0.001
CRT 266 (5.4) 339 (7.1) 298 (8.2) <0.001
All values are reported as n (%) except where indicated.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CCB, calcium channel blocker; CRT, cardiac resynchronization therapy;
ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; FI, frailty index; ICD, implantable cardioverter-defibrillator; JVD, jugular venous distension; KCCQ, Kansas City Cardiomyopathy
Questionnaire; LBBB, left bundle branch block; LVH, left ventricular hypertrophy; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; MRA, mineralocorticoid receptor antagonist; NLR,
neutrophil lymphocyte ratio; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA, New York Heart Association; PCI, primary coronary intervention; PND, paroxysmal nocturnal dyspnoea; RBBB,
right bundle branch block.
aMedian (interquartile range).
bMean± standard deviation.
cOnly cardiovascular drugs listed in the table taken into account.
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Table 3 Clinical outcomes according to frailty
FI class 1 (≤0.210)
(n = 4882)
FI class 2 (0.211–0.310)
(n = 4770)
FI class 3 (≥0.311)
(n = 3613)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary outcome
Events, n (%) 1104 (22.6) 1328 (27.8) 1314 (36.4)
Event rate per 100 pt-years (CI) 8.8 (8.3–9.3) 11.6 (11.0–12.3) 17.1 (16.2–18.0)
Unadjusted sHR 1.00 (ref) 1.35 (1.25–1.47) <0.001 1.99 (1.83–2.16) <0.001
Adjusted sHR 1.00 (ref) 1.24 (1.14–1.35) <0.001 1.71 (1.56–1.88) <0.001
First HF hospitalization
Events, n (%) 625 (12.8) 759 (15.9) 787 (21.8)
Event rate per 100 pt-years 5.0 (4.6–5.4) 6.6 (6.2–7.1) 10.2 (9.5–11.0)
Unadjusted sHR 1.00 (ref) 1.29 (1.16–1.44) <0.001 1.89 (1.69–2.11) <0.001
Adjusted sHR 1.00 (ref) 1.20 (1.07–1.34) 0.001 1.69 (1.50–1.90) <0.001
CV death
Events, n (%) 701 (14.4) 842 (17.7) 875 (24.2)
Event rate per 100 pt-years 5.3 (4.9–5.7) 6.8 (6.3–7.3) 10.0 (9.4–10.7)
Unadjusted sHR 1.00 (ref) 1.38 (1.25–1.53) <0.001 2.14 (1.92–2.38) <0.001
Adjusted sHR 1.00 (ref) 1.25 (1.12–1.39) <0.001 1.75 (1.56–1.96) <0.001
First CV hospitalization
Events, n (%) 1306 (26.8) 1605 (33.6) 1477 (40.9)
Event rate per 100 pt-years 12.8 (12.1–13.5) 18.2 (17.4–19.2) 26.5 (25.2–27.9)
Unadjusted sHR 1.00 (ref) 1.33 (1.24–1.43) <0.001 1.79 (1.65–1.93) <0.001
Adjusted sHR 1.00 (ref) 1.29 (1.19–1.39) <0.001 1.69 (1.55–1.84) <0.001
Non-CV death
Events, n (%) 137 (2.8) 176 (3.7) 188 (5.2)
Event rate per 100 pt-years 1.0 (0.9–1.2) 1.4 (1.2–1.6) 2.2 (1.9–2.5)
Unadjusted sHR 1.00 (ref) 1.34 (1.07–1.68) 0.012 1.94 (1.53–2.45) <0.001
Adjusted sHR 1.00 (ref) 1.26 (1.00–1.60) 0.053 1.75 (1.35–2.25) <0.001
First non-CV hospitalization
Events, n (%) 1088 (22.3) 1261 (26.4) 1158 (32.1)
Event rate per 100 pt-years 10.7 (10.0–11.3) 14.3 (13.6–15.1) 20.8 (19.6–22.0)
Unadjusted sHR 1.00 (ref) 1.22 (1.13–1.33) <0.001 1.62 (1.48–1.77) <0.001
Adjusted sHR 1.00 (ref) 1.17 (1.08–1.28) <0.001 1.52 (1.38–1.67) <0.001
All hospitalization/all death
Events, n (%) 2251 (46.1) 2569 (53.9) 2271 (62.9)
Event rate per 100 pt-years 22.1 (21.2–23.0) 29.2 (28.1–30.3) 40.7 (39.1–42.4)
Unadjusted HR 1.00 (ref) 1.29 (1.22–1.37) <0.001 1.77 (1.67–1.89) <0.001
Adjusted HR 1.00 (ref) 1.23 (1.16–1.31) <0.001 1.63 (1.53–1.75) <0.001
First all-cause hospitalization
Events, n (%) 1969 (40.3) 2268 (47.5) 2024 (56.0)
Event rate per 100 pt-years 19.3 (18.5–20.2) 25.8 (24.7–26.9) 36.3 (34.7–37.9)
Unadjusted sHR 1.00 (ref) 1.27 (1.19–1.34) <0.001 1.71 (1.60–1.82) <0.001
Adjusted sHR 1.00 (ref) 1.21 (1.14–1.29) <0.001 1.60 (1.49–1.71) <0.001
All-cause death
Events, n (%) 838 (17.2) 1018 (21.3) 1063 (29.4)
Event rate per 100 pt-years 6.3 (5.9–6.7) 8.2 (7.7–8.7) 12.2 (11.5–13.0)
Unadjusted HR 1.00 (ref) 1.39 (1.27–1.53) <0.001 2.19 (1.99–2.41) <0.001
Adjusted HR 1.00 (ref) 1.26 (1.14–1.39) <0.001 1.80 (1.62–2.00) <0.001
Recurrent HF hospitalizations
Total events, n 1021 1280 1426
Events per 100 pt-years 7.7 (7.2–8.2) 10.3 (9.6–10.9) 16.4 (15.5–17.2)
Unadjusted IRR 1.00 (ref.) 1.41 (1.24–1.61) <0.00 2.40 (2.09–2.76) <0.001
Adjusted IRR 1.00 (ref.) 1.25 (1.09–1.42) <0.001 1.90 (1.64–2.20) <0.001
Recurrent CV hospitalizations
Total events, n 2441 3050 3118
Events per 100 pt-years 18.3 (17.6–19.1) 24.6 (23.7–25.4) 35.8 (34.6–37.1)
Unadjusted IRR 1.00 (ref.) 1.36 (1.25–1.49) <0.001 2.03 (1.85–2.22) <0.001
Adjusted IRR 1.00 (ref.) 1.26 (1.16–1.38) <0.001 1.76 (1.60–1.95) <0.001
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 (Continued)
FI class 1 (≤0.210)
(n = 4882)
FI class 2 (0.211–0.310)
(n = 4770)
FI class 3 (≥0.311)
(n = 3613)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recurrent non-CV hospitalizations
Total events, n 1713 2132 2235
Events per 100 pt-years 12.9 (12.3–13.5) 17.2 (16.5–17.9) 25.7 (24.6–26.8)
Unadjusted IRR 1.00 (ref.) 1.30 (1.19–1.42) <0.001 1.93 (1.76–2.12) <0.001
Adjusted IRR 1.00 (ref.) 1.21 (1.11–1.33) <0.001 1.75 (1.58–1.94) <0.001
Recurrent all-cause hospitalizations
Total events, n 4154 5182 5353
Events per 100 pt-years 31.2 (30.3–32.2) 41.7 (40.6–42.9) 61.5 (59.8–63.1)
Unadjusted IRR 1.00 (ref.) 1.35 (1.26–1.44) <0.001 2.00 (1.86–2.16) <0.001
Adjusted IRR 1.00 (ref.) 1.24 (1.16–1.33) <0.001 1.76 (1.62–1.90) <0.001
Fall in KCCQ clinical summary score≥ 5 at 12months
n (%) 1598 (33.8) 1628 (35.6) 1230 (36.3)
Adjusted OR1 1.00 (ref.) 1.32 (1.20–1.45) <0.001 1.83 (1.60–2.10) <0.001
Adjusted OR2 1.00 (ref.) 1.22 (1.10–1.35) <0.001 1.62 (1.40–1.87) <0.001
CV, cardiovascular; FI, frailty index; HF, heart failure; HR, hazard ratio; IRR, incidence rate ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire; OR, odds ratio; pt,
patient; sHR, sub-distribution hazard ratio.
sHRs with 95% confidence interval (HR for all-cause death). All sHRs adjusted for region and randomized treatment at baseline. Adjusted sHRs additionally adjusted for sex,
age, heart rate, N-terminal pro brain natriuretic peptide, New York Heart Association class I/II vs. II/IV, duration of HF and ejection fraction.
Event rates per 100 patient-years with 95% confidence interval.
HF hospitalization additionally adjusted for previous hospitalization for HF.
IRRs with 95% confidence interval. All IRRs adjusted for region and randomized treatment at baseline. Adjusted IRRs additionally adjusted for sex, age, heart rate, N-terminal
pro brain natriuretic peptide, New York Heart Association class I/II vs. II/IV, duration of HF, hospitalization for HF and ejection fraction.
OR with 95% confidence interval. ORs adjusted for region and randomized treatment at baseline. Adjusted OR1 additionally adjusted for KCCQ clinical summary score at
baseline. Adjusted OR2 additionally adjusted for sex, age, heart rate, N-terminal pro brain natriuretic peptide, New York Heart Association class and ejection fraction.
are an important reminder that frailty is not confined to the
very elderly. The high prevalence of frailty in our relatively young
HFrEF population is also consistent with the hypothesis that
frailty partly reflects accelerated ageing – essentially our patients
have a prevalence of frailty usually only found in extreme old
age. Moreover, frailty seems to be particularly prevalent in HF
compared with other diseases; for example, lower frailty indices,
and lower proportion of patients classified as frail, have been
reported in chronic kidney disease, chronic obstructive pulmonary
disease, and acute coronary syndrome.23–32 Only in myeloma
patients, with a mean age of 76 years, did we find similar levels
of frailty: median FI 0.24, with 52% categorized as frail.19
Chronic inflammation, sarcopenia and general reduction in phys-
iological reserves are implicated in the pathogenesis of the frailty
syndrome.23–32 Interestingly, we found that increasing frailty was
associated with higher levels of inflammation and tissue turnover
related biomarkers, especially, growth differentiation factor 15, one
of a core panel of frailty biomarkers, thought to reflect mitochon-
drial dysfunction and cellular senescence, increased with increasing
frailty.33–38
Consistent with previous studies, a higher proportion of women
in this study were frail (68% vs. 62%), which has been attributed
to their lower muscle mass. Quality of life, overall, was lower in
women and whether this is a marker of frailty or a contributor to
frailty is unknown.
Several studies have examined frailty in HF, although most
were small and many used different methods to define frailty;
additionally, some focused on hospitalized patients or HF with .
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.. preserved ejection fraction (HFpEF) patients or included patients
without LVEFmeasurement. Only three prior studies in ambulatory
patients were large (>1000 participants) and reported clinical out-
comes. In a Spanish study, 44% of 1314 HF outpatients (76% HFrEF
and 24% HFpEF, mean age 67 years) were categorized as frail using
an approach based on four geriatric scales.39 Frailty was indepen-
dently predictive of all-cause mortality, although the multivariable
model did not include natriuretic peptides. No other outcomes
were reported. Recently, an electronic FI (eFI), calculated for 6360
patients with a diagnosis of HF (but without LVEF or natriuretic
peptides) in a large UK primary care dataset, was predictive of any
hospitalization at 1 year but not of HF hospitalization.40 Mortal-
ity was not reported. Of these patients (mean age not reported
but 83% ≥65 years), only 15% were categorized as frail using an
eFI cut-point of 0.24 compared to 51% using this threshold in our
study. Patients in the UK study had been diagnosed with HF within
the past 3 years whereas 36% of the patients in our study were
diagnosed with HF more than 5 years previously. In our patients
diagnosed with HF less than 2 years before enrolment, only 19% of
the patients had an FI ≥0.24 whereas, of those diagnosed less than
5 years before enrolment, 33% had an FI ≥0.24. Using an approach
similar to ours, the Treatment of Preserved Cardiac Function
Heart Failure with an Aldosterone Antagonist (TOPCAT) investiga-
tors reported a mean FI of 0.37± 0.11 (median 0.36; interquartile
range 0.29–0.44) in 1767 patients with HFpEF from North and
South America (mean age 71.5 years, 49% female).13 A remarkable
94% had a FI >0.21. As in this study, a higher FI was associated
with higher rates of HF hospitalization, cardiovascular death and
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Clinical outcomes according to frailty index (FI) in heart failure (HF) with reduced ejection fraction. (A) Cumulative incidence curve
of risk of first HF hospitalization or cardiovascular (CV) death. (B) Cumulative incidence curve of risk of first HF hospitalization. (C) Cumulative
incidence curve of risk of CV death. (D) Kaplan–Meier curve of all-cause death.
all-cause death, although these outcomes were not adjusted for
other predictive variables. A greater proportion of the patients in
TOPCAT had diabetes and hypertension, along with a much lower
mean KCCQ overall summary score (58.1± 23.4 vs. 72.3± 19.5 in
our patients), which could have contributed to a higher proportion
of their patients being described as frail.13 Patients with HFrEF were
also less likely to be frail than HFpEF patients in a smaller recent
study assessing different frailty tools in HF.41
The high prevalence of frailty in HFrEF is highly clinically rel-
evant, as reflected in the worse outcomes seen in frail patients.
Frail patients have reduced ability to cope with stressors that may
precipitate worsening of HF, meaning that exacerbations become
more frequent and increasingly difficult to recover from. We cer-
tainly found a marked difference in the rate of HF hospitalization
when comparing frail to non-frail patients. However, rates of
admission and deaths from other reasons were also higher in frail
individuals, although the proportion of deaths that was attributed
to non-cardiovascular causes (around 19%) was similar across FI
categories. Importantly, the absolute risks in the frailest patients
were remarkably high – e.g. 4 in 10 of the frailest individuals were
admitted to hospital at least once or died during each year of .
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. follow-up. In addition, when repeat admissions were accounted for,
the rate of hospitalization was 62 episodes per 100 patient-years.
Two recent studies using the same FI (the Hospital Frailty Risk
Score) in patients hospitalized with HF have shown that frailty is
also associated with higher rates of short and long-term mortality
after discharge; a third confirmed the distinction between frailty
and comorbidity by demonstrating a poor correlation between
the Hospital Frailty Risk Score and the Charlson Comorbidity
Index.42–44
Frailty may also reduce a patient’s ability to self-care and
impair adherence because of associated cognitive impairment.36–38
Polypharmacy increased with increasing frailty, not only causing
concerns about adherence but also about drug-related adverse
effects and interactions. Consistent with this, study drug discon-
tinuation was significantly more common in frailer patients.
The obvious question is what, if anything, can be done to prevent
or treat frailty? Frailty is believed to evolve over time, with initially
fit individuals progressing through a pre-frail stage to overt frailty
and ultimately terminal disability and death.1–5,45 Often, early frailty
may be undetected as limitations in daily activities (and associated
symptoms such as fatigue) are often attributed to the normal
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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consequences of ageing by patients and their caregivers. It is easy
to see how this could be especially so in HF. Identifying frailty early
may be important as some of the limitations caused by it may be
amenable to nutritional and lifestyle interventions and, if employed
at the pre-frail stage, these may delay progression to frailty.1,5,45–47
In this respect, cardiac rehabilitation and exercise training pro-
grammes may be particularly relevant, yet the latter was prescribed
in only around one in 10 patients in our study.48 However, as frailty
seems to reflect a number of insults to multiple systems, a multi-
faceted approach to its prevention and treatment may be required.
Concerns regarding the inclusion of the elderly and the frail
in clinical trials, either due to the perceived burden to the frail
patients or due to doubts regarding the benefit of such therapies
to the elderly and frail, exist.49 We did not see any evidence of an
interaction between treatment and frailty in the PARADIGM-HF
patients in this analysis. Similarly, other studies have also shown
that frailty does not alter the effect of therapy.20
The FI lends itself to incorporation into routine datasets, includ-
ing patient electronic health records. It is possible to conceive of
how a hospital admission record or outpatient/primary care elec-
tronic health record might automatically calculate a FI and alert the
physician/nurse to individuals with a high score, although, as alluded
to above, we do not know, yet, whether identification of frailty
should trigger any monitoring or therapeutic intervention. Like-
wise, in nationwide audits and comparison of outcomes, FI might
be an important determinant of differences in outcome that could
be adjusted for in between institution or other comparisons.
It would also be of interest to compare the Fried and Rockwood
(and other) approaches to assessing frailty and how the prevalence
of frailty varies according to the measure used and whether
different approaches are similarly predictive of outcomes.
Strengths and limitations
Our study has strengths and limitations. The patients were those
selected for inclusion in clinical trials and not fully representative
of the general population. It is likely that frailty is even more
prevalent in an unselected cohort of patients with HFrEF. Our FI
is not an independently validated prediction model and may not be
applicable to other cohorts. Also we could not test other types of
frailty scores which include tests of muscle strength and functional
capacity and we recognize that in the absence of these factors, our
current FI may be viewed as a surrogate measure of frailty. On
the other hand, we had detailed and near complete collection of
baseline variables enabling us to create the 42-item FI. We also had
careful collection of long-term adjudicated outcomes.
Conclusions
Frailty was highly prevalent in HFrEF, even in ambulatory patients
with mainly mild symptoms. Frailty was associated with greater
deterioration in quality of life and higher risk of hospitaliza-
tion and death. Frailty, did not, however, modify the effect of
sacubitril/valsartan. Strategies to prevent and treat frailty are
needed in HFrEF. ..
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Components of the frailty index (42 items) in patients
with HFrEF according to frailty.
Table S2. State of health score (EQ-5D-3L) (PARADIGM-HF only)
in patients with HFrEF according to frailty.
Table S3. Biomarkers (PARADIGM-HF only) in patients with
HFrEF according to frailty.
Table S4. Immunization and lifestyle management history
(PARADIGM-HF only) in patients with HFrEF according to
frailty.
Table S5. Clinical outcomes according to age and frailty index in
patients with HFrEF.
Table S6. Clinical outcomes in patients with HFrEF according to
frailty in patients aged ≥60 years.
Table S7. Clinical outcomes with frailty index assessed as a
continuous variable.
Table S8. Number of hospitalizations in patients according to
frailty.
Table S9. Falls and fractures in patients with HFrEF according to
frailty.
Table S10. Adverse events in patients with HFrEF according to
frailty.
Figure S1. Frailty index and the risk of all-cause death (restricted
cubic spline analysis).
Figure S2. Subgroup analysis by frailty index class. (A) Primary
composite outcome. (B) All-cause death.
Figure S3. Treatment effect of sacubitril/valsartan by frailty index
class.
Figure S4. Standard concept for assessing frailty in an ambulatory
patients with HFrEF.
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